ABT-737, a Bcl-2 inhibitor, used either as a pre-treatment or synergistically with anti-CD19 CAR T cells derived from healthy donors or from B cell ALL patients, enhanced tumor cell apoptosis [109]. This evidence concerns the gene CD19 and neoplasm.